SCHWARZ PHARMA secures future neurology projects

18-Sep-2000

SCHWARZ PHARMA and the Neurozentrum of the Universitätsklinikum Freiburg have agreed on a cooperation in the field of neuro-degenerative diseases. A whole substance class targeting this therapeutic area is to be jointly tested and further developed. UF09200 is the lead compound among these molecules.

SCHWARZ PHARMA acquires the worldwide rights to all substances originating from this cooperation that prove effective in the treatment of neuro-degenerative diseases. The project is at the early pre-clinical stage.

"This cooperation adds further attractive potential to our development pipeline. With Professor Feuerstein from the Neurologischen Univer-sitätsklinik, we have gained an excellent partner with a high international reputation in the field of neuropharmacology." said Dr. Dr. Lars Ekman, Executive Board member of SCHWARZ PHARMA AG and responsible for Research and Development. "Our aim is to continue expanding our CNS pipeline. For this reason, we are constantly exam-ining promising opportunities. We are confident that further innovative projects will follow this year."

Other news from the department

More news from our other portals

So close that even
molecules turn red...